Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Results of single arm phase IV COMACHI study

被引：0
|
作者：
Masuda, N. [1 ]
Ohtani, S. [2 ]
Nagai, S. [3 ]
Takashima, S. [4 ]
Yamaguchi, M. [5 ]
Tsuneizumi, M. [6 ]
Komoike, Y. [7 ]
Osako, T. [8 ]
Ito, Y. [9 ]
Ikeda, M. [10 ]
Ishida, K. [11 ]
Nakayama, T. [12 ]
Takashima, T. [13 ]
Asakawa, T. [14 ]
Matsumoto, S. [15 ]
Shimizu, D. [16 ]
Takahashi, M. [17 ]
机构：
[1] Natl Hosp Org Osaka Natl Hosp, Surg, Breast Oncol, Osaka, Japan
[2] Hiroshima City Hosp, Breast Surg, Hiroshima, Japan
[3] Saitama Canc Ctr, Breast & Med Oncol, Saitama, Japan
[4] Natl Hosp Org Shikoku Canc Ctr, Breast Oncol, Matsuyama, Ehime, Japan
[5] JCHO Kurume Gen Hosp, Breast Surg, Kurume, Fukuoka, Japan
[6] Shizuoka Prefectural Gen Hosp, Breast Surg, Shizuoka, Japan
[7] Kindai Univ Hosp, Surg, Sayama, Osaka, Japan
[8] Kumamoto Shinto Gen Hosp, Breast Ctr, Kumamoto, Japan
[9] JFCR, Breast Med Oncol, Canc Inst Hosp, Tokyo, Japan
[10] Fukuyama City Hosp, Breast Thyroid Gland Surg, Hiroshima, Japan
[11] Iwate Med Univ, Surg, Morioka, Iwate, Japan
[12] Osaka Int Canc Inst, Breast & Endocrine Surg, Osaka, Japan
[13] Osaka City Univ, Sch Med, Surg Oncol, Osaka, Japan
[14] Chugai Pharmaceut, Clin Informat & Intelligence Dept, Tokyo, Japan
[15] Chugai Pharmaceut, Clin Study Management, Tokyo, Japan
[16] Chugai Pharmaceut, Clin Sci & Strategy, Tokyo, Japan
[17] Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
353P
引用
收藏
页码：127 / +
页数：2
相关论文
共 50 条
  • [1] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [2] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [3] Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
    Kuemmel, Sherko
    Tondini, Carlo A.
    Abraham, Jacinta
    Nowecki, Zbigniew
    Itrych, Bartosz
    Hitre, Erika
    Karaszewska, Boguslawa
    Juarez-Ramiro, Alejandro
    Morales-Vasquez, Flavia
    Perez-Garcia, Jose Manuel
    Cardona-Huerta, Servando
    Monturus, Estefania
    Sequi, Marco
    Restuccia, Eleonora
    Benyunes, Mark
    Martin, Miguel
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (02) : 467 - 476
  • [4] Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
    Sherko Kuemmel
    Carlo A. Tondini
    Jacinta Abraham
    Zbigniew Nowecki
    Bartosz Itrych
    Erika Hitre
    Bogusława Karaszewska
    Alejandro Juárez-Ramiro
    Flavia Morales-Vásquez
    Jose Manuel Pérez-García
    Servando Cardona-Huerta
    Estefania Monturus
    Marco Sequi
    Eleonora Restuccia
    Mark Benyunes
    Miguel Martín
    [J]. Breast Cancer Research and Treatment, 2021, 187 : 467 - 476
  • [5] Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
    Tian, Tian
    Ye, Jing
    Zhou, Sihai
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 720 - 727
  • [6] CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer
    Baselga, Jose
    Swain, Sandra M.
    [J]. CLINICAL BREAST CANCER, 2010, 10 (06) : 489 - 491
  • [7] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Kerry Dwan
    Rumona Dickson
    Chris Proudlove
    Yenal Dundar
    [J]. PharmacoEconomics, 2015, 33 : 13 - 23
  • [8] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    [J]. PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
  • [9] Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancer
    Elias, A.
    Modi, S.
    Krop, I. E.
    Pegram, M.
    Ipe, D.
    Guardino, E. A.
    Althaus, B.
    LoRusso, P. L.
    [J]. CANCER RESEARCH, 2013, 73
  • [10] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Giampaolo Bianchini
    Astrid Kiermaier
    Giulia Valeria Bianchi
    Young-Hyuck Im
    Tadeusz Pienkowski
    Mei-Ching Liu
    Ling-Ming Tseng
    Mitch Dowsett
    Lila Zabaglo
    Sarah Kirk
    Tania Szado
    Jennifer Eng-Wong
    Lukas C. Amler
    Pinuccia Valagussa
    Luca Gianni
    [J]. Breast Cancer Research, 19
12345